immunoglobulin
igi
major
antibodi
chicken
transfer
larg
quantiti
egg
yolk
confer
passiv
immun
develop
embryo
igi
easili
harvest
yolk
ideal
altern
use
mammalian
igg
antibodi
follow
chapter
discuss
product
purif
igi
well
mani
advantag
applic
includ
use
igi
diagnost
analyt
tool
passiv
immunotherapi
treat
numer
health
condit
year
sinc
exist
immunoglobulin
ig
first
describ
klemper
found
major
serum
antibodi
hen
term
igi
due
enrich
egg
yolk
lesli
clem
sinc
avian
immun
system
igi
studi
extens
reveal
mani
import
characterist
applic
igi
lay
hen
ethic
altern
product
larg
quantiti
specif
antibodi
low
cost
schade
hlinak
owe
favor
immunochem
characterist
compar
mammalian
igg
igi
found
mani
applic
medic
research
field
includ
area
diagnost
biomark
discoveri
igi
perhap
receiv
attent
immunotherapeut
potenti
interact
chromatographi
hassl
aspock
immobil
metal
ion
affin
chromatographi
mccannel
nakai
green
holt
thiophil
interact
chromatographi
hansen
et
al
affin
chromatographi
use
alkalin
condit
kuronen
et
al
synthet
peptid
ligand
design
specif
immobil
igi
fassina
et
al
verdoliva
et
al
result
puriti
recoveri
dong
et
al
hernandezcampo
et
al
recent
demonstr
uf
purif
wsf
use
polyethersulphon
pe
modifi
pe
membran
increas
puriti
result
greater
igi
recoveri
recent
proteom
analysi
identif
protein
wsf
prepar
water
dilut
method
reveal
prepar
obtain
method
highli
reproduc
low
level
cholesterol
triglycerid
provid
inform
may
valuabl
predict
potenti
allerg
reaction
wsf
prepar
nilsson
et
al
use
chicken
antibodi
product
provid
sever
advantag
convent
method
igg
product
mammal
antibodi
product
chicken
much
less
invas
requir
collect
egg
rather
collect
blood
therefor
less
stress
anim
fig
karlsson
et
al
owe
genet
distanc
chicken
mammal
possibl
produc
antibodi
highli
conserv
mammalian
protein
otherwis
would
possibl
mammal
contrast
mammalian
system
much
less
antigen
requir
produc
effici
immun
respons
sustain
high
antibodi
titer
reduc
need
frequent
inject
larsson
et
al
fact
estim
product
antibodi
hen
nearli
time
greater
rabbit
base
weight
antibodi
produc
per
anim
nakai
et
al
translat
overal
reduct
anim
use
level
antibodi
product
lay
hen
typic
lay
around
egg
per
year
sim
et
al
egg
yolk
contain
mg
igi
therefor
around
g
igi
per
year
may
obtain
singl
chicken
karlsson
et
al
contrast
mammalian
serum
egg
yolk
contain
singl
class
antibodi
igi
easili
isol
yolk
precipit
techniqu
gassmann
et
al
discuss
previou
section
purifi
igi
found
stabl
year
store
larsson
et
al
although
igg
igi
share
similar
biolog
function
exist
profound
differ
chemic
structur
result
immunoreact
camenisch
et
al
zhang
contrast
igg
molecular
mass
kda
igi
molecul
molecular
mass
kda
owe
increas
number
heavychain
constant
domain
extra
pair
carbohydr
chain
hatta
et
al
sun
et
al
addit
hing
region
igi
shorter
less
flexibl
warr
et
al
content
bsheet
structur
constant
domain
igi
report
lower
shimizu
et
al
may
account
differ
stabil
observ
igi
igg
igg
igi
contain
asnlink
oligosaccharid
howev
structur
oligosaccharid
igi
differ
mammalian
igg
contain
instead
unusu
monoglucosyl
oligomannosetyp
oligosaccharid
glc
man
glcnac
structur
ohta
et
al
matsuura
et
al
isoelectr
point
igi
lower
igg
polson
et
al
igi
associ
mammalian
complement
bind
igi
human
bacteri
fcreceptor
cell
surfac
less
igg
gardner
kay
furthermor
also
suggest
igi
may
hydrophob
igg
match
lipidrich
environ
yolk
davalospantoja
et
al
gener
use
reagent
immunochem
research
purpos
antibodi
store
use
rel
mild
condit
stabil
warrant
much
attent
howev
stabil
igi
variou
process
physiolog
condit
need
consid
use
industri
food
medic
applic
shimizu
et
al
igi
stabl
ph
rang
temperatur
shimizu
et
al
howev
rang
may
extend
addit
stabil
sugar
complex
carbohydr
polyol
shimizu
et
al
chang
et
al
igi
rel
resist
treatment
trypsin
chymotrypsin
sensit
pepsin
digest
shimizu
et
al
hatta
et
al
found
almost
igi
activ
lost
follow
digest
pepsin
howev
activ
remain
even
hour
incub
trypsin
chymotrypsin
studi
human
demonstr
oral
administ
antibodi
undergo
signific
loss
activ
upon
passag
stomach
sever
report
demonstr
around
surviv
oral
administ
antibodi
similar
result
observ
adult
infant
blum
et
al
hilpert
et
al
roo
et
al
order
circumv
inactiv
igi
follow
oral
administr
number
encapsul
techniqu
examin
microencapsul
igi
use
liposom
shimizu
et
al
multipl
emuls
shimizu
nakan
previous
describ
howev
shown
limit
effect
case
destroy
antibodi
activ
encapsul
procedur
macroencapsul
igi
use
entericco
gelatin
capsul
also
examin
found
significantli
improv
antibodi
stabil
akita
nakai
use
phsensit
methacryl
acid
copolym
chitosanalgin
microcapsul
kovacsnolan
mine
li
et
al
li
et
al
also
shown
increas
igi
stabil
gastric
condit
vitro
well
vivo
immunoaffin
chromatographi
involv
specif
interact
antigen
correspond
antibodi
wide
use
purif
protein
complex
start
materi
use
process
larg
scale
limit
high
cost
techniqu
problem
relat
product
antibodi
effici
immobil
akita
lichan
specif
igi
easili
produc
larg
scale
requir
industri
applic
would
provid
ideal
replac
polyclon
monoclon
antibodi
current
use
immunoaffin
chromatographi
lichan
although
igi
sensit
low
ph
igg
found
igi
immunoaffin
column
capabl
retain
stabil
subject
standard
affin
chromatographi
condit
could
reus
time
without
signific
decreas
bind
capac
akita
lichan
recent
uniqu
featur
igi
made
advantag
use
proteom
applic
huang
et
al
deplet
abund
protein
complex
biolog
sampl
contain
wide
dynam
rang
protein
concentr
plasma
serum
urin
prior
twodimension
sodium
dodecyl
sulfat
polyacrylamid
gel
electrophoresi
sdspage
mass
spectrometri
present
signific
challeng
proteom
analysi
huang
fang
magagnotti
et
al
immunoaffin
fraction
one
effect
method
use
sampl
prepar
improv
abil
detect
lowabund
protein
huang
fang
owe
eas
product
igi
abil
produc
high
affin
antibodi
conserv
mammalian
protein
igi
wide
use
immunoaffin
protein
deplet
proteom
applic
biomark
discoveri
qian
et
al
rajic
et
al
polaskova
et
al
antibodi
serv
essenti
compon
varieti
diagnost
assay
use
qualit
quantit
determin
wide
rang
substanc
schade
hlinak
antigenbind
specif
igi
compar
igg
hatta
et
al
igi
present
sever
advantag
make
well
suit
applic
medic
diagnost
number
protein
exist
whose
amino
acid
sequenc
well
preserv
among
mammal
use
antigen
mammal
limit
antigen
hatta
et
al
evolutionari
differ
allow
product
high
avid
igi
conserv
mammalian
protein
diversifi
antibodi
repertoir
possibl
mammal
olovsson
larsson
woolley
landon
carland
et
al
use
igi
substitut
igg
clinic
test
potenti
elimin
fals
posit
often
result
low
background
less
interfer
xiao
gao
human
serum
sampl
often
contain
activ
complement
system
would
activ
mammalian
antibodi
igi
activ
human
complement
system
elimin
interfer
would
otherwis
caus
igg
larsson
mellstedt
human
serum
also
contain
rheumatoid
factor
rf
human
antimous
igg
antibodi
hama
wellknown
caus
falseposit
reaction
immunolog
assay
carland
et
al
rf
react
fc
portion
igg
hama
occur
natur
human
serum
bind
mous
antibodi
use
immunoassay
carland
et
al
sinc
igi
react
rf
larsson
sjoquist
larsson
et
al
hama
larsson
mellstedt
suggest
replac
igg
immunolog
assay
human
serum
igi
use
numer
medic
veterinari
diagnost
applic
includ
detect
quantit
cancer
biomark
breast
ovarian
cancer
nonhodgkin
lymphoma
patient
grebenschikov
et
al
alhaddad
et
al
lemami
et
al
pan
et
al
xiao
gao
diagnosi
gastric
cancer
noack
et
al
well
detect
african
horsesick
viru
du
plessi
et
al
mycobacterium
avium
subsp
paratuberculosi
shin
et
al
leptospira
spp
human
blood
vasconcello
et
al
bovin
leukemia
viru
juliarena
et
al
serotyp
footandmouth
diseas
veerasami
et
al
detect
opiat
drug
urin
gandhi
et
al
igi
sarscov
nucleocapsid
protein
incorpor
immunoswab
assay
point
care
detect
sarsinfect
individu
kammila
et
al
furthermor
igi
use
assay
involv
food
safeti
concern
includ
detect
escherichia
coli
increas
antibiot
resist
bacteria
pathogen
respond
antibiot
viral
pathogen
along
escal
number
immunocompromis
individu
prompt
much
research
administr
specif
antibodi
altern
antibiot
antimicrobi
chemotherapi
treat
infect
casadeval
scharff
reilli
et
al
igi
well
suit
passiv
immunotherapi
applic
sinc
react
rheumatoid
factor
human
fcreceptor
hama
wellknown
cell
activ
mediat
inflamm
larsson
et
al
larsson
carland
respiratori
infect
caus
colon
airway
pseudomona
aeruginosa
pa
major
caus
morbid
mortal
cystic
fibrosi
cf
patient
shale
elborn
chronic
infect
establish
difficult
elimin
even
use
antibiot
kollberg
et
al
ongo
studi
cf
patient
found
oral
rins
contain
antipa
igi
given
continu
basi
could
reduc
prevent
pa
colon
therebi
reduc
need
antibiot
treatment
carland
et
al
kollberg
et
al
nilsson
et
al
nilsson
et
al
vitro
antibodi
found
inhibit
adhes
bacteria
epitheli
cell
inhibit
bacteri
growth
suggest
igi
might
capabl
interf
bacteri
infect
process
prevent
colon
cf
patient
carland
et
al
recent
immunoreact
antibodi
examin
detail
use
matrixassist
laser
desorptionion
timeofflight
mass
spectrometri
malditofm
pa
flagellin
identifi
major
antigen
flagellin
import
establish
infect
host
well
involv
pa
chemotaxi
motil
adhes
inflamm
nilsson
et
al
result
support
abil
antipa
igi
prevent
infect
host
invas
stabil
antipa
igi
saliva
healthi
individu
also
examin
carland
et
al
antibodi
activ
remain
hour
hour
antibodi
activ
decreas
significantli
still
detect
subject
indic
oral
treatment
specif
igi
variou
local
infect
includ
common
cold
tonsil
might
also
possibl
helicobact
pylori
common
caus
gastriti
gastric
ulcer
implic
develop
gastric
carcinoma
dunn
et
al
develop
antibiot
resist
prompt
investig
altern
method
treat
prevent
h
pylori
infect
deloney
schiller
igi
produc
h
pylori
reduc
bacteri
adhes
growth
ureas
activ
vitro
decreas
h
pyloriinduc
gastric
mucos
injuri
inflamm
anim
model
shin
et
al
sinc
antibodi
produc
wholecel
h
pylori
might
crossreact
bacteria
includ
normal
human
flora
shin
et
al
product
efficaci
igi
immunodomin
h
pylori
protein
epitop
also
describ
includ
igi
ureas
nomura
et
al
ureasederiv
peptid
shin
et
al
kd
highli
reactiv
h
pylori
antigen
attallah
et
al
effect
antiureas
igi
demonstr
human
function
drink
yogurt
contain
lactobacillu
acidophilu
bifidobacterium
spp
supplement
egg
yolk
igyureas
produc
commerci
given
volunt
test
posit
h
pylori
hori
et
al
volunt
consum
igycontain
yogurt
three
time
daili
four
week
follow
urea
breath
test
valu
antigen
detect
fece
significantli
decreas
indic
suppress
h
pylori
infect
porphyromona
gingivali
one
import
caus
agent
periodont
yokoyama
et
al
vitro
antip
gingivali
igi
dosedepend
decreas
bacteri
adhes
hydrolyt
activ
yokoyama
et
al
reduc
level
p
gingivali
appli
gel
teeth
periodont
patient
yokoyama
et
al
product
igi
p
gingivali
kd
outer
membran
protein
aggreg
oral
bacteria
form
plaqu
hamajima
et
al
well
p
gingivali
hemagglutinin
haga
allow
bacteria
adher
gingiv
tissu
cell
tezuka
et
al
also
describ
found
inhibit
aggreg
hemagglutin
vitro
streptococcu
mutan
believ
princip
caus
bacterium
dental
cari
human
hamada
slade
igi
mutan
also
shown
exert
anticariogen
properti
igi
mutan
examin
passiv
prevent
dental
cari
hamada
et
al
otak
et
al
chang
et
al
found
supplement
igycontain
yolk
powder
cariogen
diet
significantli
lower
cari
score
likewis
level
mutan
decreas
volunt
gargl
mouth
rins
contain
anti
mutan
igi
hatta
et
al
igi
produc
mutan
glucan
bind
protein
b
gbpb
believ
involv
mutan
biofilm
develop
also
examin
use
rat
model
dental
cari
smith
et
al
observ
decreas
mutan
accumul
rat
treat
antigbpb
igi
well
decreas
overal
amount
dental
cari
compar
control
rat
diarrheal
diseas
continu
health
problem
worldwid
especi
develop
countri
estim
respons
million
infant
death
per
year
estradagarcia
et
al
well
caus
econom
loss
livestock
especi
neonat
calv
piglet
morri
sojka
one
promin
caus
diarrheal
diseas
remain
escherichia
coli
number
strategi
prevent
e
coli
infect
use
igi
examin
product
igi
fimbrial
antigen
porcin
enterotoxigen
e
coli
etec
describ
igi
inhibit
bind
e
coli
strain
porcin
epitheli
cell
porcin
intestin
mucu
jin
et
al
vitro
given
oral
piglet
antibodi
dosedepend
protect
e
coli
infect
marquardt
et
al
also
found
oral
administr
igi
result
surviv
etecinfect
piglet
compar
control
group
reduct
incid
sever
diarrhea
passiv
protect
effect
antietec
igi
neonat
calv
also
shown
calv
fed
milk
contain
igi
transient
diarrhea
surviv
good
bodi
weight
gain
cours
studi
recent
igi
recombin
adherenceassoci
protein
e
coli
shown
reduc
adher
vitro
cultur
cell
suggest
may
potenti
reduc
e
coli
colon
host
cattl
human
cook
et
al
similarli
girard
et
al
demonstr
igi
produc
virul
factor
attach
effac
e
coli
aeec
reduc
bacteri
adher
porcin
enteropathogen
e
coli
well
heterolog
aeec
strain
includ
human
bovin
canin
enteropathogen
e
coli
found
oral
administr
antibodi
reduc
e
coliinduc
lesion
pig
challeng
porcin
enteropathogen
e
coli
strain
furthermor
anti
coli
igi
found
reduc
e
coli
number
improv
intestin
health
chicken
challeng
e
coli
mahdavi
et
al
igi
mastitiscaus
e
coli
dosedepend
inhibit
e
coli
growth
enhanc
phagocyt
activ
vitro
zhen
et
al
amar
et
al
demonstr
vitro
anti
coli
effect
igi
epec
shiga
toxinproduc
e
coli
stec
stec
suggest
possibl
futur
therapeut
use
human
salmonella
enteritidi
se
salmonella
typhimurium
st
main
caus
salmonellosi
outbreak
human
infect
chicken
e
n
lee
et
al
salmonella
possess
sever
surfac
compon
virul
relat
includ
outer
membran
protein
omp
isibasi
et
al
flagella
fla
strain
fimbrial
antigen
thorn
et
al
thorn
et
al
abil
igi
specif
omp
lp
flagella
fla
passiv
protect
experiment
salmonellosi
mice
demonstr
vitro
use
cultur
human
intestin
cell
line
chalghoumi
et
al
found
igi
omp
se
st
reduc
salmonellainduc
decreas
transepitheli
electr
resist
ter
infect
cell
monolay
block
salmonella
sp
adhes
concentrationdepend
manner
suggest
passiv
immun
salmonella
ompspecif
igi
could
use
prevent
salmonella
colon
broiler
chicken
subsequ
carcass
contamin
process
vivo
mice
challeng
se
st
treatment
igi
omp
lp
fla
result
significantli
higher
surviv
rate
compar
control
mice
yokoyama
et
al
salmonella
infect
calv
also
signific
problem
st
dublin
account
case
salmonellosi
passiv
protect
st
dublin
investig
challeng
calv
se
dublin
oral
administ
antis
anti
dublin
igi
control
calv
die
within
day
wherea
fever
diarrhea
observ
calv
given
high
titer
igi
yokoyama
et
al
rotaviru
major
caus
acut
gastroenter
infant
develop
develop
countri
clark
et
al
vivo
igi
produc
murin
human
simian
strain
rotaviru
prevent
rotavirusinduc
diarrhea
mice
yolken
et
al
ebina
antirotaviru
effect
seen
administ
viral
challeng
suggest
use
prevent
treatment
rotaviru
gastroenter
hatta
et
al
product
igi
recombin
rotaviru
coat
protein
kovacsnolan
et
al
zhang
et
al
also
describ
igi
exhibit
signific
neutral
activ
human
rotaviru
hrv
vitro
suggest
potenti
use
prevent
treatment
rotaviru
human
neonat
calf
diarrhea
caus
bovin
rotaviru
brv
signific
caus
mortal
cattl
lee
et
al
use
mous
model
brv
infect
kuroki
et
al
observ
protect
two
strain
brv
use
oral
administ
antibrv
igi
passiv
protect
calv
brv
infect
use
antibrv
igi
also
demonstr
kuroki
et
al
inflammatori
bowel
diseas
ibd
includ
crohn
diseas
ulcer
coliti
character
chronic
inflamm
gastrointestin
tract
podolski
treatment
typic
involv
corticosteroid
immunosuppress
agent
howev
shown
limit
therapeut
efficaci
associ
sever
side
effect
longterm
toxic
atreya
neurath
tumor
necrosi
factor
tnf
one
key
proinflammatori
cytokin
involv
pathogenesi
ibd
garsid
immunotherapi
use
monoclon
mous
antibodi
tnfa
approv
use
howev
costli
advers
side
effect
report
patient
receiv
system
antitnf
therapi
sandborn
hanauer
worledg
et
al
report
oral
administ
antitnfa
igi
capabl
effect
treat
acut
chronic
phase
coliti
rat
well
neutral
human
tnfa
vitro
indic
possibl
use
treatment
ibd
human
yersinia
ruckeri
caus
enter
redmouth
diseas
system
bacteri
septicemia
salmonid
fish
stevenson
et
al
persist
ruckeri
carrier
fish
shed
bacteria
fece
present
continu
sourc
infect
lower
mortal
rate
reduc
infect
rate
observ
rainbow
trout
fed
antiy
ruckeri
igi
given
challeng
ruckeri
white
spot
syndrom
viru
wssv
caus
high
mortal
larg
econom
loss
cultur
shrimp
lu
et
al
igi
produc
wssv
shown
passiv
protect
shrimp
lu
et
al
crayfish
lu
et
al
edwardsiella
tarda
fish
pathogen
spread
infect
intestin
mucosa
edwardsiellosi
japanes
eel
seriou
problem
eel
farm
industri
especi
due
appear
antibioticresist
strain
hatta
et
al
eel
challeng
e
tarda
given
anti
tarda
igi
surviv
without
symptom
infect
contrast
control
eel
die
within
day
gutierrez
et
al
hatta
et
al
antibodi
use
commerci
follow
field
test
nearli
tail
cultur
eel
confirm
diseas
prevent
anti
tarda
igi
hatta
et
al
specif
igi
shown
effect
prevent
treat
sever
diseas
includ
passiv
protect
chick
infecti
bursal
diseas
viru
ibdv
eterradossi
et
al
yousif
et
al
avian
coccidiosi
caus
eimeria
spp
lee
et
al
b
protect
piglet
porcin
epidem
viru
pedv
kweon
et
al
protect
calv
bovin
coronaviru
bcv
ikemori
et
al
protect
dog
canin
van
nguyen
et
al
igi
also
shown
effect
candida
albican
dosedepend
prevent
c
albican
growth
adher
biofilm
format
vitro
wang
et
al
fujibayashi
et
al
prevent
colon
mice
ibrahim
el
et
al
final
product
test
igi
influenza
viru
also
describ
administ
infect
igi
prevent
mice
infect
significantli
reduc
viral
replic
result
complet
recoveri
diseas
suggest
igi
may
safe
afford
altern
method
control
influenza
outbreak
nguyen
et
al
envenom
result
bite
venom
snake
scorpion
spider
import
public
health
hazard
mani
region
particularli
tropic
subtrop
countri
wide
use
treatment
direct
inject
specif
antivenom
often
antibodi
produc
hors
sheep
neutral
toxic
potenti
lethal
effect
venom
gutierrez
et
al
sever
report
product
neutral
venom
chicken
antivenom
igi
paul
et
al
meenatchisundaram
et
al
b
araujo
et
al
includ
product
polyval
antiafrican
snake
venom
igi
use
bite
sever
differ
snake
de
almeida
et
al
igi
found
higher
bioactiv
antivenom
tradit
rais
hors
thalley
carrol
de
almeida
et
al
also
lower
likelihood
produc
side
effect
serum
sick
anaphylact
shock
occur
upon
administr
mammalian
serum
protein
thalley
carrol
staphylococc
enterotoxin
famili
bacteri
superantigen
produc
staphylococcu
aureu
associ
number
seriou
diseas
includ
food
poison
toxic
shock
syndrom
fraser
et
al
specif
igi
shown
inhibit
product
aureu
enterotoxina
vitro
sugitakonishi
et
al
also
report
igi
aureu
enterotoxinb
seb
system
administ
challeng
could
protect
rhesu
monkey
toxic
shock
syndrom
leclair
et
al
suggest
might
use
prevent
treatment
lethal
dose
aureu
enterotoxin
could
use
reduc
elimin
enterotoxinmedi
disord
anti
aureu
igi
also
use
veterinari
applic
found
inhibit
aureu
growth
vitro
zhen
et
al
guimara
et
al
prevent
bovin
mastiti
caus
aureu
cattl
administ
intramammari
infus
rabi
remain
major
public
health
problem
develop
countri
claim
live
estim
peopl
year
ertl
infect
rabi
viru
caus
enceph
human
case
fatal
rate
almost
johnson
et
al
motoi
et
al
b
report
product
antirabi
igi
rais
part
g
protein
rabi
viru
vitro
antibodi
bound
virion
cell
infect
rabi
viru
neutral
rabi
viru
infect
administr
antirabi
igi
mice
infect
rabi
viru
reduc
mortal
caus
viru
suggest
igi
direct
rabi
viru
g
protein
could
serv
possibl
altern
current
avail
antirabi
human
equin
immunoglobulin
motoi
et
al
transgen
pig
promis
donor
organ
xenotransplant
share
mani
anatom
physiolog
characterist
human
klymiuk
et
al
howev
one
import
barrier
xenograft
hyperacut
reject
mediat
natur
antibodi
human
pig
antigen
complement
fixat
rapid
onset
intravascular
coagul
sandrin
mckenzi
major
target
natur
antibodi
carbohydr
epitop
express
mammal
except
human
ape
monkey
besid
human
monkey
chicken
also
lack
express
bouhour
et
al
sinc
igi
bind
human
complement
fcreceptor
antiag
igi
may
suitabl
candid
use
block
antibodi
inhibit
interact
may
contribut
xenograft
reject
fryer
et
al
demonstr
antiag
igi
block
human
xenoreact
antibodi
bind
porcin
rat
tissu
vitro
inhibit
lysi
porcin
cell
human
serum
suggest
igi
could
potenti
use
inhibit
pigtohuman
xenograft
reject
antiag
igi
also
found
significantli
reduc
infect
porcin
endogen
retroviru
perv
agal
bear
viru
emerg
potenti
zoonot
agent
possibl
pigtohuman
transmiss
leventh
et
al
product
igi
chicken
extract
specif
antibodi
egg
yolk
increasingli
attract
interest
scientif
commun
evidenc
signific
growth
amount
igyrel
literatur
schade
et
al
inde
immun
hen
repres
ideal
altern
effici
gener
larg
quantiti
polyclon
antibodi
sinc
hous
inexpens
egg
collect
nonstress
noninvas
isol
purif
igi
rel
simpl
highyield
zhang
recent
also
suggest
select
transport
igi
blood
egg
yolk
may
also
provid
new
strategi
deliv
substanc
egg
yolk
attempt
produc
design
egg
bae
et
al
may
expand
applic
igi
immun
protocol
adjuv
system
continu
modifi
order
increas
specif
antibodi
product
identif
product
igi
new
antigen
continu
lead
new
applic
egg
yolk
antibodi
human
health
research
applic
oral
passiv
immun
dental
cari
rat
use
hen
egg
yolk
antibodi
specif
cellassoci
glucosyltransferas
streptococcu
mutan
infect
immun
hamajima
maruyama
hijiya
hatta
h
abiko
egg
yolkderiv
immunoglobulin
igi
porphyromona
gingivali
outer
membran
protein
inhibit
coaggreg
activ
arch
oral
biol
hansen
p
scobl
j
hanson
b
hoogenraad
n
j
isol
purif
immunoglobulin
chicken
egg
use
thiophil
interact
chromatographi
j
immunol
method
hassl
aspock
h
purif
egg
yolk
immunoglobulin
twostep
procedur
use
hydrophob
interact
chromatographi
gel
filtrat
j
immunol
method
hatta
h
sim
j
nakai
separ
phospholipid
egg
yolk
recoveri
watersolubl
protein
journal
food
scienc
hatta
h
kim
yamamoto
novel
isol
method
hen
egg
yolk
antibodi
igi
agric
biol
chem
hatta
h
tsuda
k
akachi
kim
yamamoto
product
properti
egg
yolk
antibodi
igi
human
rotaviru
compar
rabbit
igg
biosci
biotechnol
biochem
hatta
h
tsuda
k
akachi
kim
yamamoto
ebina
oral
passiv
immun
effect
antihuman
rotaviru
igi
behavior
proteolyt
enzym
biosci
biotechnol
biochem
